Carregant...
Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice
BACKGROUND: The clinical need to be able to administer high doses of intravenous iron conveniently as a rapid infusion has been addressed by the recent introduction of ferric carboxymaltose and subsequently iron isomaltoside 1000. Neither requires a test dose. The maximum dose of ferric carboxymalto...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3253757/ https://ncbi.nlm.nih.gov/pubmed/22241947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S25882 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|